Filing Flows › Iovance Biotherapeutics (IOVA) › R&D spending
Iovance Biotherapeutics (IOVA) R&D spending by quarter
Iovance Biotherapeutics' R&D spending was $49.3M in Q3 2026 (third quarter 2026), -16% from Q2 2026. Over the last 7 quarters it ranged from $49.3M (Q3 2026) to $77.9M (Q2 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $49.3M | -16% | -34% |
| Q2 2026 | $58.9M | -6% | -24% |
| Q1 2026 | $62.5M | -12% | -18% |
| Q4 2025 | $71.2M | -5% | — |
| Q3 2025 | $75.2M | -4% | — |
| Q2 2025 | $77.9M | +3% | — |
| Q1 2025 | $76.0M | — | — |
Q3 2026 at a glance
Iovance Biotherapeutics, Q3 2026: revenue $121M (+80% year over year), operating margin -19.7%, net loss $22.3M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Iovance Biotherapeutics' R&D spending?
Iovance Biotherapeutics' R&D spending was $49.3M in Q3 2026 (third quarter 2026), -16% from Q2 2026.
How has Iovance Biotherapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $49.3M (Q3 2026) to $77.9M (Q2 2025).
Q3 2026 results → · How Iovance Biotherapeutics makes money →